

INDICATION	STUDY NAME, DESIGN	REGIMEN	STATUS
Desmoid Tumors	AL-DES-01, RINGSIDE	AL102 (Gamma-secretase inhibitor)	OPEN (Part B)
Tenosynovial Giant Cell Tumor	MOTION, Phase III, Deciphera	Vimseltinib (DCC3014), CSF-1 inhibitor	OPEN
Locally advanced resectable retroperitoneal sarcomas	GEIS 37 (TRASTS), Phase II	Neoadjuvant Trabectedin + RT	OPEN
Resectable RTP sarcoma	Cebiotex, Phase I	Adjuvant CEB-01 in surgical bed	OPEN
Advanced STS, First line	FIBROSARC	Doxo vs Doxo + L19TNF	OPEN
Advanced LMS or UPS, first line	GEIS 69 (IMMUNOSARC), Phase Ib	Doxo+DTIC + Nivolumab (LMS) Epi-Ifo + Nivo (UPS)	OPEN
Advanced deddif liposarcoma	Brightline-1, Phase II/III	Doxo vs BI907828 vs Doxo + BI907828	OPEN
Advanced STS, second lines	GEIS- 83 (PRIME), Phase I/II	PM-14 (ecubectedin) PM-14 + RT (cohorts C,D)	OPEN
Advanced STS, second lines	GEIS 75 (Synergias), Phase II	Trabectedin + RT	OPEN
Advanced STS, second lines	GEIS 67 (SELISARC), Phase I/II	Gemcitabine+selinexor	OPEN
Advanced STS, second lines	GEIS 69, IMMUNOSARC, Phase II	Sunitinib + nivolumab	OPEN
Advanced synovial sarcoma and myxoid liposarcoma	SPEARHEAD, Cellular therapy	TCR lymphocytes targeting MAGE-A4	OPEN
Advanced synovial sarcoma and myxoid liposarcoma	GSK, Cellular therapy	TCR lymphocytes targeting NY-ESO 1 Letetresgene autoleucel (lete-cel, GSK3377794)	OPEN (only first line)
Advanced synovial sarcoma	PM1183-A-014-15, Phase I/II	Lurbinectedin + CPT-11	OPEN
Advanced osteosarcoma, first line	GEIS 69 (IMMUNOSARC), Phase Ib	MAP + Nivolumab	OPEN

Advanced osteosarcoma and chondrosarcoma, second line	GEIS 75 (Synergias), Phase II	Trabectedin + RT	OPEN
Advanced chondrosarcoma	INBRX-109, Randomized Phase II,	INBRX-109 (DR-5 inhibitor) vs placebo	OPEN
Advanced chordoma	GEIS 51 (PABLOSARC), Phase II	Palbociclib	OPEN
Advanced Ewing sarcoma	rEECur Phase II/III study	HD Ifosfamide vs ICE	OPEN
Advanced Ewing sarcoma	J1S-MC-JP04, Randomized Phase II	Temozolomide + CPT-11 +/- abemaciclib	Activation September 2022
Advanced STS, First line, Elderly patients	TOLERANCE, Phase III	Doxo 75 vs Weekly Doxo vs metronomic cyclophosphamide	Activation Q3 2022
Advanced STS, First line	GEIS 74 (LIXTE)- ENHANCER	Doxo + LB100 (phosphatase inhibitor)	Activation Q3 2022
Advanced STS, First line	GEIS 73 (MONOPAR), Phase III	Doxo vs camsirubicina	Activation Q3 2022
Advanced STS (several histotypes)	FLASH (Phillogen PH-L19TNFSARC 03-18)	DTIC vs DTIC + L19TNF	Activation Q3 2022
Advanced Leiomyosarcoma	PTC, Phase II/III	DTIC vs DTIC + unesbulin	Activation Q3 2022
Tenosynovial Giant Cell Tumor	SNX-301-020 (TANGENT), Phase III	Emactuzumab (CSF-1 inhibitor)	Activation Q3 2022
Advanced sarcoma	ADCT-601-102,	AXL inhibitor	Activation Q2-3 2022
Advanced solid tumors	IK-930-001, Phase I	TEAD inhibitor	Activation Q3 2022
Advanced CIC-DUX sarcoma	REGOBONE, Phase II	Regorafenib vs placebo	Activation Q3 2022

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
LOCALLY AGGRESSIVE ENTITIES					
DESMOID TUMORS	AL-DES-01, RINGSIDE Ayala Therapeutics Phase II/III	AL102 (Gamma-secretase inhibitor)	- PART A: <ul style="list-style-type: none"> • 18 y • Desmoid tumors • Clinical/radiological (>10%) PD - PART B: <ul style="list-style-type: none"> • >12 y • Radiological RECIST PD (previous 12 months) 	- PART A: <ul style="list-style-type: none"> • Prior Notch inhibitor • Contraindication for MRI - PART B: <ul style="list-style-type: none"> • Prior Notch inhibitor 	OPEN (Part A)
Tenosynovial Giant Cell Tumor	MOTION, Phase III Deciphera	Vimseltinib (DCC3014), CSF-1 inhibitor	<ul style="list-style-type: none"> • 18y • Diagnosis of TGCT • Symptomatic (BPI>4) 	<ul style="list-style-type: none"> • Previous CSF-1 inhibitor 	OPEN
Tenosynovial Giant Cell Tumor	SNX-301-020 (TANGENT), Phase III	Emactuzumab (CSF-1 inhibitor)	<ul style="list-style-type: none"> • 12y • Diagnosis of TGCT • Unresectable or morbid surgery 	<ul style="list-style-type: none"> • Liver disease • Previous CSF_1 inhibitor in the previous 4 w 	Activation Q3 2022

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
LOCALIZED RETROPERITONEAL STS					
Locally advanced resectable retroperitoneal sarcomas	GEIS 37 (TRASTS), Phase II	Neoadjuvant Trabectedin + RT	<ul style="list-style-type: none"> • 18-75y • G2-3 LMS, Dediff lipo, pleomorphic lipo • Resectable disease • Amenable for RT 	<ul style="list-style-type: none"> • Previous therapy • ECOG >1 	OPEN
Resectable retroperitoneal sarcoma	Cebiotex, Phase I	Adjuvant CEB-01 in surgical bed	<ul style="list-style-type: none"> • 18 • Locally advanced/recurrent retroperitoneal STS • ECOG 0-1 	<ul style="list-style-type: none"> • ECOG >1 	OPEN

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
Localized high-risk GIST	GEIS 42, Phase III	Imatinib 2 years vs follow-up after completion of 3 years of adjuvant imatinib	<ul style="list-style-type: none"> • High-risk GIST • Adjuvant IM for 3 years with no interruptions 	<ul style="list-style-type: none"> • Dose reduction • Less than 35 months of adjuvant therapy 	OPEN (closes end of September 2022)

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
FIRST LINE ADVANCED STS					
Advanced STS, First line	FIBROSARC (Phillogen), Phase III NCT04650984	Doxo vs Doxo + L19TNF	<ul style="list-style-type: none"> • 18-75y • Grade 2-3 Advanced STS (Several subtypes) 	<ul style="list-style-type: none"> • Previous systemic therapy for advanced disease • Previous anthacycline • Hepatitis B, C • ECOG >2 	OPEN
Advanced LMS or UPS, first line	GEIS 69 (IMMUNOSARC), Phase Ib	Doxo+DTIC + Nivolumab (LMS) Epi-Ifo + Nivo (UPS)	<ul style="list-style-type: none"> • 18-80y • Advanced LMS or UPS ECOG 0-1 	<ul style="list-style-type: none"> • Previous therapy with anthracyclines (Previous adjuvant gem-docetaxel is allowed) • Previous therapy for advanced disease 	OPEN
Advanced dedifferentiated liposarcoma	Brightline-1 (Boehringer) Phase II/III	Doxo vs BI907828 (MDM2 inh) vs Doxo + BI907828	<ul style="list-style-type: none"> • 18y • Dedifferentiated liposarcoma • No previous therapy 	<ul style="list-style-type: none"> • Previous therapy • P53 mutation • CNS disease 	OPEN
Advanced STS, First line, Eldery patients	TOLERANCE, Phase III (EORTC)	Doxo 75 vs Weekly Doxo vs metronomic cyclophosphamide	<ul style="list-style-type: none"> • >70y or >65 (G8 score<14) • Advanced STS (Several subtypes) 	<ul style="list-style-type: none"> • Previous systemic therapy for advanced disease • Previous anthacycline 	Activation Q3 2022

Advanced STS, First line	GEIS 74 (LIXTE)- ENHANCER, Phase I/II	Doxo + LB100 (phosphatase inhibitor)	<ul style="list-style-type: none"> • 18 y • Advanced STS (Several subtypes) • Feasibility for tumoral biopsies 	<ul style="list-style-type: none"> • Previous systemic therapy • Hepatitis B, C • ECOG >1 	Activation Q3-4 2022
Advanced STS, First line	GEIS 73 (MONOPAR), Phase III	Doxo vs camsirubicina	<ul style="list-style-type: none"> • 18 y • Advanced STS (Several subtypes) 	<ul style="list-style-type: none"> • Previous systemic therapy 	Activation Q3-4 2022

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
SECOND AND FURTHER LINES ADVANCED STS					
Advanced STS, second lines	GEIS- 83 (PRIME), Phase I/II	PM-14 (ecubectedin) PM-14 + RT (cohorts C,D)	<ul style="list-style-type: none"> • 18-75y • Advanced STS Advanced solid tumors (Cohort C + RT) Localized STS (cohort D + RT) • One previous line of therapy 	<ul style="list-style-type: none"> • ECOG >1 • More than 2 previous lines for advanced disease 	OPEN (cohorts A, B)
Advanced STS, second lines	GEIS 75 (Synergias), Phase II	Trabectedin + RT	<ul style="list-style-type: none"> • 16-75y • Advanced STS (including rhabdo, desmoplasic, Ewing) • Symptomatic disease amenable for RT • Previous anthracycline 	<ul style="list-style-type: none"> • ECOG >1 • More than 3 previous lines for advanced disease 	OPEN
Advanced STS, second lines	GEIS 67 (SELISARC), Phase I/II (now open Phase II)	Gemcitabine+selinexor	<ul style="list-style-type: none"> • 18-80y • LMS, UPS, MPNST, ASPS • Previous anthracycline 	<ul style="list-style-type: none"> • ECOG>1 • More than 3 previous lines • Previous gemcitabine or seli 	OPEN
Advanced STS, second lines	GEIS 69, IMMUNOSARC Phase II	Sunitinib + nivolumab	<ul style="list-style-type: none"> • 12-80y • Diagnosis: - Vascular sarcoma (angio, EHE, intimal) 	<ul style="list-style-type: none"> • More than 3 previous lines for advanced disease 	OPEN

			<ul style="list-style-type: none"> - Clear cell sarcoma - Alveolar soft-part sarcoma - Extraskeletal myxoid chondrosarcoma 		
Advanced synovial sarcoma and myxoid liposarcoma	Adaptimmune (ADP-0044-002 SPEARHEAD), NCT04044768 Cellular therapy	TCR lymphocytes targeting MAGE-A4	<ul style="list-style-type: none"> • Advanced SS or MLPS • 18y • HLA A 02 + • MAGE-A4 + 	<ul style="list-style-type: none"> • Screening negative 	OPEN
Advanced synovial sarcoma and myxoid liposarcoma	GSK NCT03967223 Cellular therapy	TCR lymphocytes targeting NY-ESO 1 Letetresgene autoleucel (lete-cel, GSK3377794)	<ul style="list-style-type: none"> • Advanced SS or MLPS • 18y • HLA A 02 + • NY-ESO 1 + 	<ul style="list-style-type: none"> • Screening negative 	OPEN (only first line)
Advanced synovial sarcoma	PM1183-A-014-15, Phase I/II	Lurbinectedin + CPT-11	<ul style="list-style-type: none"> • 18y • STS (including Synovial) 	<ul style="list-style-type: none"> • More than 2 previous lines for advanced disease 	OPEN
Advanced tumors with MDM2 amplification	Boehringer	BI9078282 (inh MDM2) Basket Phase Ib	<ul style="list-style-type: none"> • 18 y • Advanced Tumors harboring MDM2 amplification 	<ul style="list-style-type: none"> • No limit of previous lines 	Activation september 2022
Advanced STS (several histotypes)	FLASH (Phillogen PH-L19TNFSARC 03-18)	DTIC vs DTIC + L19TNF	<ul style="list-style-type: none"> • 18-80y • Grade 2-3 Advanced STS (Several subtypes) • At least 2 previous therapies for advanced 	<ul style="list-style-type: none"> • Previous DTIC ot previous L19TNF • Hepatitis B, C • ECOG >2 	Activation Q3 2022

			disease (including anthracyclines)		
Advanced Leiomyosarcoma	PTC, Phase II/III	DTIC vs DTIC + unesbulin	<ul style="list-style-type: none"> • 18 y • Diagnosis of leiomyosarcoma • At least 1 previous line therapy 	<ul style="list-style-type: none"> • Previous DTIC or TMZ 	Activation Q3 2022
Advanced sarcoma	ADCT-601-102, Phase I ADC therapeutics	AXL inhibitor	<ul style="list-style-type: none"> • 18y • Sarcoma (STS, bone) • Solid tumors 		Activation Q2-3 2022
Advanced solid tumors	IK-930-001, Ikena therapeutics Phase I	TEAD inhibitor	<ul style="list-style-type: none"> • 18 y • TAZ-CAMPTA1 or YAP1-TFE3 epithelioid hemangioendotelioma (cohort 3) 	<ul style="list-style-type: none"> • Proteinuria > 150mg/dl • CNS metastasis 	Activation Q2-3 2022

INDICATION	STUDY NAME, DESIGN	REGIMEN	INCLUSION CRIT	EXCLUSION CRIT	STATUS
ADVANCED BONE SARCOMAS					
Advanced osteosarcoma, first line	GEIS 69 (IMMUNOSARC), Phase Ib	MAP + Nivolumab	<ul style="list-style-type: none"> • 12-40 y • Recent diagnosis of metastatic osteosarcoma • Resectable primary tumor - 	<ul style="list-style-type: none"> • Previous therapy • Paraosteal, periosteal osteosarcoma 	OPEN
Advanced osteosarcoma and chondrosarcoma, second line	GEIS 75 (Synergias), Phase II	Trabectedin + RT	<ul style="list-style-type: none"> • 16-75y • Advanced bone sarcoma (osteo, chondro) • Symptomatic disease amenable for RT • Previous anthracycline 	<ul style="list-style-type: none"> • ECOG >1 • More than 3 previous lines for advanced disease 	OPEN
Advanced chondrosarcoma	INBRX-109, Randomized Phase II, Inhibrx	INBRX-109 (DR-5 inhibitor) vs placebo	<ul style="list-style-type: none"> • 18y • Advanced conventional chondrosarcoma (G1-3) 	<ul style="list-style-type: none"> • Previous DR5 inhibitor • Non-conventional chondrosarcoma 	OPEN

Advanced chordoma	GEIS 51 (PABLOSARC), Phase II	Palbociclib	<ul style="list-style-type: none"> Advanced chordoma RECIST progression P16 expression low 	<ul style="list-style-type: none"> ECOG>2 	OPEN
Advanced Ewing sarcoma	rEECur Phase II/III study	HD Ifosfamide vs ICE	<ul style="list-style-type: none"> Advanced Ewing sarcoma 6m-50y Measurable disease 	<ul style="list-style-type: none"> Previous treatment with this regimens 	OPEN
Advanced chondrosarcoma	INBRX-109, Randomized Phase II, Inhibrx	INBRX-109 (DR-5 inhibitor) vs placebo	<ul style="list-style-type: none"> 18y Advanced conventional chondrosarcoma (G1-3) 	<ul style="list-style-type: none"> Previous DR5 inhibitor Non-conventional chondrosarcoma 	OPEN
Advanced Ewing sarcoma	J1S-MC-JP04 Randomized Phase II	Temozolomide + CPT-11 +/- abemaciclib	<ul style="list-style-type: none"> 1-40y Advanced histologically confirmed Ewing sarcoma 	<ul style="list-style-type: none"> Previous CDK4 inh Progression to previous TEMIRI 	Activation September 2022
Advanced CIC-DUX sarcoma	REGOBONE, Phase II	Regorafenib vs placebo	<ul style="list-style-type: none"> 18 Advanced CIC-DUX 		Activation Q2-3 2022